SRP8053

IL-35 (mouse): FC (human)

recombinant, expressed in CHO cells

• Synonyme(s) : Interleukin-35, T-cell immunoglobulin and mucin domain-containing protein 4
• Code UNSPSC : 12352200
• Nomenclature NACRES : NA.32

Propriétés

• Source biologique: human; mouse
• Produit recombinant: expressed in CHO cells
• Pureté: ≥98% (SDS-PAGE)
• Forme: lyophilized
• Poids mol.: monomer 23 kDa by calculation (IL-12a (p35)); monomer 46 kDa by calculation (Ebi3)
• Conditionnement: pkg of 5 μg
• Technique(s): activity assay: suitable
• Impuretés: <0.06 EU/μg endotoxin, tested
• Couleur: white
• Numéro d'accès UniProt: O35228; P43431
• Conditions d'expédition: wet ice
• Température de stockage: −20°C
• Informations sur le gène: mouse ... Ebi3(50498) , Il12a(16159)

Description

Description générale

Research area: IMMUNO AND CKS. Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs.

Application

IL-35 has been used to study its immunosuppressive effect on acute graft-versus-host disease in a mouse model.Ithas also been used to study its effects on the differentiation of granulocytemacrophage-colony-stimulating factor-producing T helper cells (ThGM). IL-35has been used to study its effects on bleomycin-induced pulmonary fibrosis.

Actions biochimiques/physiologiques

Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells′ ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.IL-35 is produced inresponse to agonists of toll-like receptors 3 and 4 (TLR 3 & 4) and interferon γ (IFN-γ). It is secreted mainly by activated B cells, CD4⁺ Foxp3⁺ regulatoryT cells (Tregs), and at a lower concentration by monocytes, smooth muscle cells, and endothelial cells.

Forme physique

Lyophilized from 0.2 μm-filtered solution in PBS.

Reconstitution

Reconstitute at 100 μg/mL in sterile PBS.

Autres remarques

The mouse IL-35 complex composed of the Ebi3 subunit (aa 23-228) and the IL-12a (p35) subunit (aa 23-215) is fused through a polypeptide linker to the Fc region of human IgG1.

Informations sur la sécurité

• Code de la classe de stockage: 10 - Combustible liquids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable